Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Inflammation
Published in: Inflammation 6/2011

01-12-2011

Berberine Inhibits Inflammatory Response and Ameliorates Insulin Resistance in Hepatocytes

Authors: Tianjiong Lou, Zhongai Zhang, Zhilei Xi, Kang Liu, Lin Li, Baolin Liu, Fang Huang

Published in: Inflammation | Issue 6/2011

Login to get access

Abstract

Berberine, a major isoquinoline alkaloid present in Chinese herb Rhizoma coptidis, is a potent inhibitor of inflammation and has anti-diabetic activity. This study aims to investigate effects of berberine on ameliorating insulin resistance and molecular mechanisms involved in HepG2 cells. Inflammatory responses and insulin resistance were induced by palmitate (PA) stimulation for 24 h. Treatment of berberine enhanced insulin-mediated glycogen synthesis and restored insulin inhibition of triglyceride secretion. Stimulation of PA resulted in IL-6 and TNF-α production in HepG2 cells, and antibody-neutralizing assay further confirmed that IL-6 and TNF-α were involved in the development of insulin resistance. Berberine effectively inhibited IL-6 and TNF-α production in a concentration-dependent manner, demonstrating its anti-inflammatory activity in hepatocytes. Meanwhile, PA-evoked inflammation impaired insulin signaling cascade and berberine improved insulin signaling cascade by modification of Ser/Thr phosphorylation of insulin receptor substrate-1(IRS-1) and downstream Akt (T308). Above results suggest that berberine improved insulin sensitivity in PA-stimulated hepatocytes and this regulation might relative with its anti-inflammatory activity.
Literature
1.
Mokdad, A.H., E.S. Ford, B.A. Bowman, W.H. Dietz, F. Vinicor, V.S. Bales, and J.S. Marks. 2003. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. Journal of the American Medical Association 289: 76–79.PubMedCrossRef
2.
Hotamisligil, G.S., N.S. Shargill, and B.M. Spiegelman. 1993. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science 259: 87–91.PubMedCrossRef
3.
Feinstein, R., H. Kanety, M.Z. Papa, B. Lunenfeld, and A. Karasik. 1993. Tumor necrosis factor-α suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. Journal of Biological Chemistry 268: 26055–26058.PubMed
4.
Hotamisligil, G.S. 2003. Inflammatory pathways and insulin action. International Journal of Obesity and related Metabolic Disorders 27(Suppl 3): S53–S55.PubMedCrossRef
5.
Moller, D.E. 2000. Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trends in Endocrinology and Metabolism 11: 212–217.PubMedCrossRef
6.
Yuan, M., N. Konstantopoulos, J. Lee, L. Hansen, Z.W. Li, M. Karin, and S.E. Shoelson. 2001. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkβ. Science 293: 1673–1677.PubMedCrossRef
7.
Hundal, R.S., K.F. Petersen, A.B. Mayerson, P.S. Randhawa, S. Inzucchi, S.E. Shoelson, and G.I. Shulman. 2002. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. Journal of Clinical Investigation 109: 1321–1326.PubMed
8.
Kuhlmann, J., C. Neumann-Haefelin, U. Belz, J. Kalisch, H.P. Juretschke, M. Stein, E. Kleinschmidt, W. Kramer, and A.W. Herling. 2003. Intramyocellular lipid and insulin resistance: a longitudinal in vivo 1 H-spectroscopic study in Zucker diabetic fatty rats. Diabetes 52: 138–144.PubMedCrossRef
9.
Dresner, A., D. Laurent, M. Marcucci, M.E. Griffin, S. Dufour, G.W. Cline, L.A. Slezak, D.K. Andersen, R.S. Hundal, D.L. Rothman, K.F. Petersen, and G.I. Shulman. 1999. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. Journal of Clinical Investigation 103: 253–259.PubMedCrossRef
10.
Cai, D., M. Yuan, D.F. Frantz, P.A. Melendez, L. Hansen, J. Lee, and S.E. Shoelson. 2005. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nature Medicine 11(2): 183–190.PubMedCrossRef
11.
Seppälä-Lindroos, A., S. Vehkavaara, A.M. Häkkinen, T. Goto, J. Westerbacka, A. Sovijärvi, J. Halavaara, and H. Yki-Järvinen. 2002. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. Journal of Clinical Endocrinology and Metabolism 87: 3023–3028.PubMedCrossRef
12.
Ryysy, L., A.M. Häkkinen, T. Goto, S. Vehkavaara, J. Westerbacka, J. Halavaara, and H. Yki-Järvinen. 2000. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 49: 749–758.PubMedCrossRef
13.
Lau, C.W., X.Q. Yao, Z.Y. Chen, W.H. Ko, and Y. Huang. 2001. Cardiovascular actions of berberine. Cardiovascular Drug Reviews 19: 234–244.PubMedCrossRef
14.
Zhang, Y., X. Li, D. Zou, W. Liu, J. Yang, N. Zhu, L. Huo, M. Wang, J. Hong, P. Wu, G. Ren, and G. Ning. 2008. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. Journal of Clinical Endocrinology and Metablism 93: 2559–2565.CrossRef
15.
Lee, Y.S., W.S. Kim, K.H. Kim, M.J. Yoon, H.J. Cho, Y. Shen, J.M. Ye, C.H. Lee, W.K. Oh, C.T. Kim, C. Hohnen-Behrens, A. Gosby, E.W. Kraegen, D.E. James, and J.B. Kim. 2006. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes 55: 2256–2264.PubMedCrossRef
16.
Yin, J., R. Hu, M. Chen, J. Tang, F. Li, Y. Yang, and J. Chen. 2002. Effects of berberine on glucose metabolism in vitro. Metabolism 51: 1439–1443.PubMedCrossRef
17.
Leng, S.H., F.E. Lu, and L.J. Xu. 2004. Therapeutic effects of berberine in impaired glucose tolerance rats and its influence on insulin secretion. Acta Pharmacological Sinica 25: 496–502.
18.
Ko, B.S., S.B. Choi, S.K. Park, J.S. Jang, Y.E. Kim, and S. Park. 2005. Insulin sensitizing and insulinotropic action of berberine from Coptidis Rhizoma. Biological and Pharmaceutical Bulletin 28: 1431–1437.PubMedCrossRef
19.
Jeong, H.W., K.C. Hsu, J.W. Lee, M. Ham, J.Y. Huh, H.J. Shin, W.S. Kim, and J.B. Kim. 2009. Berberine suppresses proinflammatory responses through AMPK activation in macrophages. American Journal of Physiology-Endocrinology and Metabolism 296: 955–964.CrossRef
20.
Choi, B.H., I.S. Ahn, Y.H. Kim, J.W. Park, S.Y. Lee, C.K. Hyun, and M.S. Do. 2006. Berberine reduces the expression of adipogenic enzymes and inflammatory molecules of 3T3–L1 adipocyte. Experimental and Molecular Medicine 38: 599–605.PubMed
21.
Baldeweg, S.E., A. Golay, A. Natali, B. Balkau, S. Del Prato, and S.W. Coppack. 2000. Insulin resistance, lipid and fatty acid concentrations in 867 healthy Europeans. European Group for the Study of Insulin Resistance (EGIR). European Journal of Clinical Investigation 30: 45–52.PubMedCrossRef
22.
Bradford, M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry 72: 248–254.PubMedCrossRef
23.
Bolinder, J., D.A. Kerckhoffs, E. Moberg, E. Hagstrom-Toft, and P. Arner. 2000. Rates of skeletal muscle and adipose tissue glycerol release in nonobese and obese subjects. Diabetes 49: 797–802.PubMedCrossRef
24.
Boden, G. 1997. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 46: 3–10.PubMedCrossRef
25.
Kelley, D.E., and L.J. Mandarino. 2000. Fuel selection in human skeletal muscle in insulin resistance: a reexamination. Diabetes 49: 677–683.PubMedCrossRef
26.
Lewis, G.F., A. Carpentier, K. Adeli, and A. Giacca. 2002. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocrine Reviews 23: 201–229.PubMedCrossRef
27.
Kelley, D.E., T.M. McKolanis, R.A. Hegazi, L.H. Kuller, and S.C. Kalhan. 2003. Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance. American Journal of Physiology 285: 906–916.
28.
Shi, H., M.V. Kokoeva, K. Inouye, I. Tzameli, H. Yin, and J.S. Flier. 2006. TLR4 links innate immunity and fatty acid-induced insulin resistance. Journal of Clinical Investigation 116: 3015–3025.PubMedCrossRef
29.
Jeong, H.W., K.C. Hsu, J.W. Lee, M. Ham, J.Y. Huh, H.J. Shin, W.S. Kim, and J.B. Kim. 2009. Berberine suppresses pro-inflammatory responses through AMPK activation in macrophages. American Journal of Physiology-Endocrinology and Metabolism 296: E955–E964.PubMedCrossRef
30.
Senn, J.J., P.J. Klover, I.A. Nowak, and A. Robert. 2002. Mooney Interleukin-6 Induces Cellular Insulin Resistance in Hepatocytes. Diabetes 51: 3391–3399.PubMedCrossRef
31.
Hotamisligil, G.S., P. Peraldi, A. Budavari, R. Ellis, M.F. White, and B.M. Spiegelman. 1996. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α and obesity-induced insulin resistance. Science 1996(271): 665–668.CrossRef
32.
Uysal, K.T., S.M. Wiesbrock, M.W. Marino, and G.S. Hotamisligil. 1997. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 389: 610–614.PubMedCrossRef
33.
Hotamisligil, G.S., A. Budavari, D. Murray, and B.M. Spiegelman. 1994. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes central role of tumor necrosis factor-α. Journal of Clinical Investigation 94: 1543–1549.PubMedCrossRef
34.
Cheung, A.T., D. Ree, J.K. Kolls, J. Fuselier, D.H. Coy, and M. Bryer-Ash. 1998. An in vivo model for elucidation of the mechanism of tumor necrosis factor—(TNF-α)-induced insulin resistance: evidence for differential regulation of insulin signaling by TNF-α. Endocrinology 139: 4928–4935.PubMedCrossRef
35.
Cheung, A.T., J. Wang, D. Ree, J.K. Kolls, and M. Bryer-Ash. 2000. Tumor necrosis factor-induces hepatic insulin resistance in obese Zucker (fa/fa) rats via interaction of leukocyte antigen-related tyrosine phosphatase with focal adhesion kinase. Diabetes 49: 810–819.PubMedCrossRef
36.
Yamada, Y., E.M. Webber, I. Kirillova, J.J. Peschon, and N. Fausto. 1998. Analysis of liver regeneration in mice lacking type 1 or type 2 tumor necrosis factor receptor: requirement for type 1 but not type 2 receptor. Hepatology 28: 959–970.PubMedCrossRef
37.
Campbell, J.S., L. Prichard, F. Schaper, J. Schmitz, A. Stephenson-Famy, M.E. Rosenfeld, G.M. Argast, P.C. Heinrich, and N. Fausto. 2001. Expression of suppressors of cytokine signaling during liver regeneration. Journal of Clinical Investigation 107: 1285–1292.PubMedCrossRef
38.
Senn, J.J., P.J. Klover, I.A. Nowak, and R.A. Mooney. 2002. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 12: 3391–3399.CrossRef
39.
Liu, Y.F., A. Herschkovitz, H.S. Boura, D. Ronen, K. Paz, D. Leroith, and Y. Zick. 2004. Serine phosphorylation proximal to its phosphotyrosine binding domain inhibits insulin receptor substrate 1 function and promotes insulin resistance. Molecular and Cellular Biology 24: 9668–9681.PubMedCrossRef
40.
Liu, Y.F., K. Paz, A. Herschkovitz, A. Alt, T. Tennenbaum, S.R. Sampson, M. Ohba, T. Kuroki, D. LeRoith, and Y. Zick. 2001. Insulin stimulates PKCzeta-mediated phosphorylation of insulin receptor substrate-1 (IRS-1). A self-attenuated mechanism to negatively regulate the function of IRS proteins. Journal of Biological Chemistry 276: 14459–14465.PubMed
41.
Park, E., V. Wong, X. Guan, A.I. Oprescu, and A. Giacca. 2007. Salicylate prevents hepatic insulin resistance caused by short-term elevation of free fatty acids in vivo. Journal of Endocrinology 2: 323–331.CrossRef
42.
Shi, Shu, Liu Xiaomei, Song Lina, Zhou Jinfang, Song Jumin. 2009. Effect of berberine on the gene expression of IRS-1/-2, p85 in 2-type diabetic rats. Zhejiang Journal of Traditional Chinese Medicine 44: 254–257.
43.
Toker, A., and A.C. Newton. 2000. Akt/protein kinase B is regulated by autophosphorylation at the hypothetical PDK-2 site. Journal of Biological Chemistry 12: 8271–8274.CrossRef
44.
Kim, S.H., E.J. Shin, E.D. Kim, T. Bayaraa, S.C. Frost, and C.K. Hyun. 2007. Berberine activates GLUT1-mediated glucose uptake in 3 T3-L1 adipocytes. Biological & Pharmaceutical Bulletin 30: 2120–2105.CrossRef
Metadata
Title
Berberine Inhibits Inflammatory Response and Ameliorates Insulin Resistance in Hepatocytes
Authors
Tianjiong Lou
Zhongai Zhang
Zhilei Xi
Kang Liu
Lin Li
Baolin Liu
Fang Huang
Publication date
01-12-2011
Publisher
Springer US
Published in
Inflammation / Issue 6/2011
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-010-9276-2

Other articles of this Issue 6/2011

Inflammation 6/2011 Go to the issue

OriginalPaper

Postnatal Development of Hepatic Innate Immune Response

OriginalPaper

Luteolin Prevents LPS-Induced TNF-α Expression in Cardiac Myocytes Through Inhibiting NF-κB Signaling Pathway

OriginalPaper

Fish Oil, but Not Soy Bean or Olive Oil Enriched Infusion Decreases Histopathological Severity of Acute Pancreatitis in Rats Without Affecting Eicosanoid Synthesis

OriginalPaper

Dynamics of Inflammatory Markers in Post-Acute Stroke Patients Undergoing Rehabilitation

OriginalPaper

The Transcriptional Activation of the Cyclooxygenase-2 Gene in Zymosan-Activated Macrophages is Dependent on NF-Kappa B, C/EBP, AP-1, and CRE Sites

OriginalPaper

Effects of Caffeic Acid Phenethyl Ester (CAPE) on Hepatopulmonary Syndrome
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits